Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
- Update frequency
- every 13 days
- Average duration
- 25 minutes
- Episodes
- 116
- Years Active
- 2021 - 2025
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant
We love to hear from our listeners. Send us a message.
Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech America…
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
We love to hear from our listeners. Send us a message.
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's…
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang
We love to hear from our listeners. Send us a message.
In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) prod…
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
We love to hear from our listeners. Send us a message.
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to …
Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.
We love to hear from our listeners. Send us a message.
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-b…
The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz
We love to hear from our listeners. Send us a message.
Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Labor…
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
We love to hear from our listeners. Send us a message.
On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host E…
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
We love to hear from our listeners. Send us a message.
The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Pod…
Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's prop…
4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
We love to hear from our listeners. Send us a message.
Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challeng…
Cell Therapy For Corneal Endothelial Dystrophies With Aurion Biotech's Greg Kunst
We love to hear from our listeners. Send us a message.
For this third and final episode recorded at ARM's 2023 Meeting on the Mesa, Cell & Gene: The Podcast Host, Erin Harris, sat down with Greg Kunst…
Overcoming the Limitations of CAR T-Cell Therapy with Vittoria Bio's Nick Siciliano, Ph.D.
We love to hear from our listeners. Send us a message.
Vittoria Biotherapeutics’ CEO, Nick Siciliano, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss the company's mission to …
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson
We love to hear from our listeners. Send us a message.
Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation at Astellas sat down with Cell & Gene: The Podcast's Erin Harris at…
The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
We love to hear from our listeners. Send us a message.
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's prog…
Inside 2023 Meeting on the Mesa with ARM's COO, Rita Johnson-Greene
We love to hear from our listeners. Send us a message.
Alliance for Regenerative Medicine's COO, Rita Johnson-Greene, joined Cell & Gene: The Podcast host, Erin Harris, in person at the 2023 Meeting o…
The Future of Cell and Organ Transplantation in Treating T1D with Dr. Camillo Ricordi
We love to hear from our listeners. Send us a message.
A pioneer and an icon in diabetes research, Camillo Ricordi, M.D., is the Professor of Surgery, Director of Cell Transplant Center and Director E…
In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
We love to hear from our listeners. Send us a message.
Umoja Biopharma's CEO, Andy Scharenberg, M.D., joins Cell & Gene: The Podcast's Erin Harris to discuss the evolution of allogeneic, in vivo CAR-T…
Inside Genome Editing with CBER's Dr. Peter Marks
We love to hear from our listeners. Send us a message.
The FDA's Center for Biologics Evaluation and Research (CBER)'s Dr. Peter Marks makes his second appearance on Cell & Gene: The Podcast. This tim…
The Future of CAR-T with Bristol Myers Squibb's Lynelle Hoch
We love to hear from our listeners. Send us a message.
As SVP Cell Therapy Franchise Lead at Bristol Myers Squibb, Lynelle Hoch leads her team to bring more curative cell-based therapies to patients. …
The Promise of Genome Editing with Caribou Biosciences' Rachel Haurwitz, Ph.D.
We love to hear from our listeners. Send us a message.
On this episode of Cell & Gene: The Podcast, Rachel Haurwitz, Ph.D., CEO at Caribou Biosciences joins Host Erin Harris to discuss the evolution o…